TransMedics Group, Inc 10-Q for FY2026 Q3
TransMedics Group, Inc. (TMDX)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 06, 2026
About this 10-Q
TransMedics Group, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
TransMedics Group, Inc. generated total revenue of $566.9 million and net income of $39.1 million for the nine months ended September 30, 2026, while research, development, clinical trials and administrative expenses increased. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $203.01M
- up 41.1% from $143.82M a year earlier
- Net income
- $17.07M
- down 29.8% from net income of $24.32M a year earlier
- Diluted EPS
- $0.46
- down 30.3% from $0.66 a year earlier